Hostname: page-component-848d4c4894-xfwgj Total loading time: 0 Render date: 2024-06-28T16:13:01.723Z Has data issue: false hasContentIssue false

Acute Confusional Syndrome and Covid-19 disease. Clinical and Sociodemographic differences with other comorbid diseases

Published online by Cambridge University Press:  01 September 2022

D. García Hernández*
Affiliation:
Parc de Salut Mar, Instituto De Neuropsiquiatría Y Adicciones (inad), Barcelona, Spain
M. Calls Samora
Affiliation:
Parc de Salut Mar, Instituto De Neuropsiquiatría Y Adicciones (inad), Barcelona, Spain
A. Llimona González
Affiliation:
Parc de Salut Mar, Instituto De Neuropsiquiatría Y Adicciones (inad), Barcelona, Spain
F. Dinamarca
Affiliation:
Parc de Salut Mar, Institut De Neuropsiquiatria I Addiccions (inad), Barcelona, Spain
F. Casanovas
Affiliation:
Parc de Salut Mar, Institut De Neuropsiquiatria I Addiccions (inad), Barcelona, Spain
A. Pérez Oms
Affiliation:
Parc de Salut Mar, Instituto De Neuropsiquiatría Y Adicciones (inad), Barcelona, Spain
C. Llimona Sánchez
Affiliation:
Parc de Salut Mar, Institut De Neuropsiquiatria I Addiccions (inad), Barcelona, Spain
S. Oller Canet
Affiliation:
Parc de Salut Mar, Instituto De Neuropsiquiatría Y Adicciones (inad), Barcelona, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Coronavirus Disease 19 (COVID-19) was declared a pandemic by the World Health Organization (WHO) in March 2020. Since the outbreak, neuropsychiatric presentations such as delirium have been developing.

Objectives

Our aim is to describe sociodemographic and clinical differences between inpatients cursing with Acute Confusional Syndrome (ACS) with and without COVID-19 pneumonia.

Methods

This is an observational-descriptive study. All patients attended by the liaison psychiatry service of Hospital del Mar, between February and April 2020, with ACS diagnosis were included. The sample was divided in 2 groups (with and without COVID-19 pneumonia). Sociodemographic and clinical variables including sex, age, previous somatic or psychiatric history, ACS risk factors, ACS subtype and pharmacological treatment were compared. Chi-square and U Mann Whitney tests were used.

Results

The total sample was 62 patients. 43.5% were women with a mean age of 71,7 (SD 11,3). Covid pneumonia group included 26 patients. There was a higher percentage of Hypoxemia in Covid pneumonia patients (p<0,001). There were significant differences between Covid pneumonia group and ACS in relation to: a previous diagnosis of Ischemic Heart Disease (p=0,007), Heart Failure (p=0,029) and Nephropathy (p=0,022). Dexmedetomidine (p=0,001) was highly used for ACS treatment in Covid pneumonia patients.

Conclusions

In this sample, patients with ACS and Covid pneumonia had a bigger rate of hypoxemia and previous history of Ischemic Heart Disease, Heart Failure and Nephropathy compared to the rest of ACS patients. Dexmedetomidine was more commonly used for the treatment of ACS in Covid pneumonia group. More studies would be necessary to assess the significance.

Disclosure

No significant relationships.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.